<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01233167</url>
  </required_header>
  <id_info>
    <org_study_id>SRRSH-CVD-001</org_study_id>
    <nct_id>NCT01233167</nct_id>
  </id_info>
  <brief_title>Effect of Different Anti-platelet Strategies on the Long-term Outcome After Sirolimus Drug-eluting Stent Implantation</brief_title>
  <acronym>EASTS</acronym>
  <official_title>Benefits and Risks Evaluation of Different Anti-platelet Strategies Beyond a 12-month Period Inpatients Receiving Sirolimus Drug-eluting Stent Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sir Run Run Shaw Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to assess the effectiveness of dual antiplatelet therapy, aspirin alone versus
      steeply discontinued clopidogrel plus aspirin in preventing clinical MACE events.Our subject
      is beyond a 12-month period patients receiving sirolimus drug-eluting stent implantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is not clear that dual antiplatelet therapy is better than aspirin beyond 12-months period
      patients receiving sirolimus drug-eluting stent implantation. If aspirin plus clopidogrel
      reduced MACE rates without increasing blood events, the investigators will evaluate
      risk-benefit ratio. The investigators will observe all cause mortality, nonfatal myocardial
      infarction, or clinical-driven target vessel revascularization TVR in a 1-year trial
      duration. In addition, strokes, stent thrombosis, cardiac re-hospitalizations,
      dialysis/hemofiltration, duration of hospitalization and bleeding events will be observed.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">May 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>all cause mortality</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>nonfatal myocardial infarction</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical-driven target vessel revascularization</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>cardiac death</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>stent thrombosis</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>death</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial infarction</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>any repeat revascularization</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>strokes</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dialysis/hemofiltration</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding events</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">5232</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>steply discontinued clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>clopidogrel 75 mg po per day for 12 months</description>
    <arm_group_label>clopidogrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo 75mg po per day for 12 months</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel and placebo</intervention_name>
    <description>clopidogrel 50mg per day for 3 months,clopidogrel 25mg per day for 3 months,then placebo 75mg per day for 6 months</description>
    <arm_group_label>steply discontinued clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years of older.

          -  The latest PCI with DES implantation before 12 months (stents must be one or more
             sirolimus-eluting stents).

          -  Angiographically confirmed major epicardial vessels (&gt;=2.5mm in diameter) without
             significant stenosis or restenosis (&gt;=50%).

          -  Geographically accessible and willing to come in for required study visits.

          -  Signed informed consent.

        Exclusion Criteria:

          -  The patient has a known hypersensitivity or contraindication to aspirin and
             clopidogrel.

          -  Severe congestive heart failure (class III or IV according to NYHA, or pulmonary
             edema) at the time of enrollment and within 12 months.

          -  EF&lt;35% within 12 months.

          -  Severe cardiac valves disease, or idiopathic cardiomyopathy such as dilated
             cardiomyopathy, hypotrophic cardiomyopathy. Other severe system diseases.

          -  Previous ACS within 12 months.

          -  Previous stroke or transient ischemia attack within 12 months.

          -  Previous myocardial infarction and clinical-driven target vessel revascularization
             within 12 months.

          -  Current enrollment in another clinical trial.

          -  Suspected pregnancy.

          -  Big bleeding events within 12 months.

          -  Planned surgical procedure.

          -  Previous other type DES implantation or BMS implantation history.

          -  Extra-cardiac stent implantation history.

          -  Current or planned dialysis.

          -  The patient has a known hypersensitivity or contraindication to statins.

          -  Current or planned high dose and long-term glucocorticoid treatment.

          -  that is expected to limit survival to less than 1 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>He Huang, Doctor of Medicine</last_name>
    <phone>860571-86006246</phone>
    <email>huanghell@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guo-sheng Fu, Doctor of Philosopy</last_name>
    <phone>860571-86006490</phone>
    <email>fugs64@gmail.com</email>
  </overall_contact_backup>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2010</study_first_submitted>
  <study_first_submitted_qc>November 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2010</study_first_posted>
  <last_update_submitted>July 19, 2011</last_update_submitted>
  <last_update_submitted_qc>July 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Guosheng Fu, director of cardiovascular department</name_title>
    <organization>Sir Run Run Shaw Hospital, College of medicine, Zhejiang University</organization>
  </responsible_party>
  <keyword>dual antiplatelet therapy</keyword>
  <keyword>sirolimus drug-eluting stent</keyword>
  <keyword>major adverse cardiac events</keyword>
  <keyword>bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

